Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mast cells initiate lymphocyte egress from distant lymph nodes upon skin inflammation via RANKL/sphingosine-1-phosphate axis
Konstantinos Katsoulis-Dimitriou, Waqar Umer, Laura Knop, Tanja Schickschneit, Aaron Hoffmann, Ali El-Bizri, Lea M. Schmitter, Kathleen Baumgart, Nouria Jantz-Naeem, Vladyslava Dovhan, Charlotte Heidelbach, Lars Philipsen, Andreas J Müller, Stephan Fricke, Sascha Kahlfuß, Thomas Schüler, Jan Dudeck, Anne Dudeck
Konstantinos Katsoulis-Dimitriou, Waqar Umer, Laura Knop, Tanja Schickschneit, Aaron Hoffmann, Ali El-Bizri, Lea M. Schmitter, Kathleen Baumgart, Nouria Jantz-Naeem, Vladyslava Dovhan, Charlotte Heidelbach, Lars Philipsen, Andreas J Müller, Stephan Fricke, Sascha Kahlfuß, Thomas Schüler, Jan Dudeck, Anne Dudeck
View: Text | PDF
Research Article Dermatology Immunology Inflammation

Mast cells initiate lymphocyte egress from distant lymph nodes upon skin inflammation via RANKL/sphingosine-1-phosphate axis

  • Text
  • PDF
Abstract

Receptor activator of NF-κB ligand (RANKL) is important for bone metabolism, but also modulates immune processes. We showed that mast cells (MCs) were involved in RANKL regulation, but the importance of MC-derived RANKL in skin inflammation has not, to our knowledge, been investigated. In contact hypersensitivity (CHS), the absence of MC-derived RANKL led to reduced skin inflammation due to impaired leukocyte infiltration and blood lymphopenia. Surprisingly, we observed a massive hyperplasia of the distant inguinal lymph nodes (LNs) in the absence of MC RANKL. Using adoptive transfers, flow cytometry, and whole-mount 3D imaging, we demonstrated that this was not caused by structural maladaptation, but rather by the inability of lymphocytes to exit in a timely manner. Importantly, RANKL deletion in skin MCs only replicated the effect of LN hyperplasia and blood lymphopenia. Moreover, MCs were involved in serum sphingosine-1-phosphate (S1P) regulation during sensitization and challenge. Intravascular administration of S1P restored timely lymphocyte egress, demonstrating a MC-induced, organ-spanning RANKL/S1P axis. Consequently, peripheral skin MC–derived RANKL was essential for the timely lymphocyte egress from distant LNs, which may have important implications for the targeted treatment of inflammatory skin diseases.

Authors

Konstantinos Katsoulis-Dimitriou, Waqar Umer, Laura Knop, Tanja Schickschneit, Aaron Hoffmann, Ali El-Bizri, Lea M. Schmitter, Kathleen Baumgart, Nouria Jantz-Naeem, Vladyslava Dovhan, Charlotte Heidelbach, Lars Philipsen, Andreas J Müller, Stephan Fricke, Sascha Kahlfuß, Thomas Schüler, Jan Dudeck, Anne Dudeck

×

Figure 6

S1P administration rescues LN lymphocyte retention in MCΔRANKL mice.

Options: View larger image (or click on image) Download as PowerPoint
S1P administration rescues LN lymphocyte retention in MCΔRANKL mice.
(A)...
(A) LECs were sorted from ear skin and expanded in vitro and then treated with PCMC supernatants that were either activated for 2 hours or 24 hours via the FceR in vitro (anti–DNP-IgE for 24 hours followed by DNP BSA). LECs were also treated with recombinant RANKL (green line) or were untreated (black line). S1P expression was measured in the supernatants. (B) MCΔRANKL or MCWT were DNFB sensitized and challenged after 6 days, and a kinetic assay of S1P was performed during sensitization and up until 48 hours after challenge. (C) Recombinant RANKL was injected i.d. into the ear and 2 hours after serum S1P was measured. (D) Two hours after challenge, 500 ng S1P (+) or PBS only as a control (–) was i.v. injected. Flow cytometric measurements of skin, blood, and LN lymphocytes were performed 24 hours after challenge. (E) Total numbers of lymphocytes infiltrating the ear skin. (F) Blood lymphocyte numbers per 100 μL blood. (G) Total numbers of lymphocytes in inguinal LNs. All graphs are depicted as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by Kruskal-Wallis test (A, E, F, G), or 2-way ANOVA (B), both with correction for multiple comparisons, or by Mann-Whitney U test (C).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts